Moderna reshuffles executives ahead of possible launches

• Ester Banque from Zoetis joins as chief commercial officer, while President Stephen Hoge will oversee infectious disease, intismeran (cancer vaccine developed with Merck), and rare disease divisions
• Moderna expects potential pivotal trial results this year for intismeran and a propionic acidemia treatment, which could enable its first oncology and rare disease product launches
• The company anticipates launching up to three new products in 2027-2028 (flu-COVID combo, seasonal flu, and norovirus vaccines), with FDA decision on flu vaccine mFlusiva expected by August 5

Moderna Reshuffles Executives Ahead of Possible Launches

Key Executive Changes:

Moderna announced significant leadership restructuring on June 16 to prepare for anticipated product launches over the next several years. Ester Banque, former president of U.S. operations at Zoetis, has been appointed chief commercial officer. President Stephen Hoge will expand his responsibilities to oversee infectious disease, oncology (intismeran), and rare disease divisions.

Pipeline Developments:

The company expects critical clinical milestones in 2024, including potential pivotal trial results for:

• Intismeran: Moderna's lead mRNA-based cancer vaccine developed with Merck
• Propionic acidemia treatment: Targeting a rare inherited metabolic disorder

Positive trial outcomes could enable Moderna's first launches in oncology and rare diseases.

Near-Term Regulatory Actions:

The FDA will hold an advisory committee meeting on June 18 to review Moderna's experimental flu vaccine, mFlusiva, with a final decision expected by August 5.

Future Product Timeline:

Moderna anticipates launching up to three new products in 2027-2028:

• Flu plus COVID combination vaccine
• Seasonal flu vaccine
• Norovirus vaccine

Market Implications:

This executive reorganization signals Moderna's strategic shift beyond its COVID-19 franchise toward diversification into oncology, rare diseases, and respiratory vaccines. The leadership changes position the company to commercialize its expanding mRNA platform across multiple therapeutic areas, potentially reducing revenue dependence on COVID vaccines. Near-term catalysts include the June FDA advisory meeting and August regulatory decision on mFlusiva, which could validate Moderna's mRNA technology in seasonal respiratory vaccines and drive investor confidence.